Fair Value Calculator Fair Value Calculator
EN DE

1134 (1134) Fair Value & Analysis

Healthcare · Market cap HK$173M

1 1134 1134 · HK
PriceHK$0.3450
Fair ValueHK$0.0900
Upside-73.9%
Quality69/100
Evidence: Medium Range HK$0.0800 – HK$0.0900

Fair value as of: Jul 2, 2026

From 10 valuation models · updated today

Share price −4.2% over the past month.

Price vs Fair Value (12 months)

HK$0.3850 HK$0.1710 Fair Value HK$0.0900 Jun 2025 Jun 2026

12‑month range HK$0.1710 – HK$0.3850 · fair‑value band HK$0.0800 – HK$0.0900 · the HK$0.3450 price screens above the HK$0.0900 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1134 (1134) currently trades at HK$0.3450, while our model-based Fair Value estimate is HK$0.0900 — implying the stock looks roughly 73.9% overvalued today. We read business quality at 69/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 1134 generated revenue of HK$500M at a net margin of -3.0%. Revenue grew 0.6% year over year. It earns a return on equity of -10.0%. The balance sheet holds a net cash position of HK$39.5M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$500M
Revenue growth (YoY) +0.6%
Net margin -3.0%
Return on equity -10.0%
Free cash flow HK$23.3M FY2025
Operating margin -3.2%
More key figures
EPS (TTM) HK$-0.0100
EPS growth (YoY) -58.4%
Net cash HK$39.5M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1134 reported revenue of HK$500M in FY2025 versus HK$435M in FY2021, a compound +3.6%/yr. Reported net income was −HK$15.1M in FY2025.

Revenue +3.6%/yr
FY21 HK$435M
FY22 HK$465M
FY23 HK$393M
FY24 HK$454M
FY25 HK$500M
Net income
FY21 −HK$2.1M
FY22 HK$9.2M
FY23 HK$1.4M
FY24 −HK$21.6M
FY25 −HK$15.1M

Is 1134 fairly valued? → Check now

Similar stocks

6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.95 $182.39 -55%
EssilorLuxottica Société anonyme ESLOF $190.25 $125.65 -34%
HOYA Corporation HOCPY $162.33 $101.00 -38%
Medline Inc MDLN $33.61 $31.78 -5%
Becton, Dickinson and Company BDX $143.92 $104.17 -28%
Alcon Inc ALC $66.11 $36.99 -44%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 1134 (1134) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.0900 versus a price of HK$0.3450 — about −74% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 1134?
Our model-based fair value for 1134 is HK$0.0900 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.3450.
What is the quality score of 1134?
1134 has a Quality Score of 69/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 1134 (1134)?
1134 reported trailing-twelve-month revenue of about HK$500M (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 1134?
The net profit margin of 1134 is about -3.0%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.